Business ❯ Pharmaceuticals ❯ Biotechnology

Vaccine Development

COVID-19 Vaccines Acquisition Market Performance

Pfizer’s mRNA Flu Shot Tops Standard Vaccine in Large Phase 3 Trial

Regulatory uncertainty now determines whether the candidate advances to U.S. authorization.

Sanofi Signs $1.15 Billion Deal to Acquire Vicebio’s Molecular Clamp Respiratory Vaccine Platform